scPharmaceuticals (SCPH) - 2024 Q4 - Annual Results

Revenue Performance - Preliminary unaudited fourth quarter FUROSCIX net revenue is expected to be in the range of $12.0 million to$12.3 million, representing a 22% increase from the third quarter of 2024 at the mid-point of the range [8]. - Preliminary unaudited full year 2024 FUROSCIX net revenue is expected to be in the range of $36.2 million to$36.5 million, representing 167% growth over the full year 2023 at the mid-point of the range [8]. Product Shipment - Approximately 13,300 FUROSCIX doses shipped in the fourth quarter, representing an approximately 23% increase from the 10,800 doses shipped in the third quarter of 2024 [8]. Financial Metrics - The gross-to-net discount is expected to be in the range of 18% to 19%, compared to the gross-to-net discount of 15.7% in the third quarter of 2024 [8]. - Unaudited cash, cash equivalents and short-term investments were approximately $75.7 million as of December 31, 2024, which does not include an approximate increase in accounts receivable of 27% over the balance as of September 30, 2024 [8]. Operational Improvements - A specialty pharmacy was added to improve coverage of expanded geography [8].